The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).
Nan Du
No relevant relationships to disclose
Junxun Ma
No relevant relationships to disclose
Shan Wang
No relevant relationships to disclose
Xiaosong Li
No relevant relationships to disclose
Junzhong Sun
No relevant relationships to disclose
Huanrong Kang
No relevant relationships to disclose
Yan Fu
No relevant relationships to disclose
Hui Zhao
No relevant relationships to disclose
Yi Hu
No relevant relationships to disclose